Stay updated with breaking news from Rr Development Core Team. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
This clinical trial assesses the efficacy and adverse events of adjunctive intravenous low-dose methylprednisolone to endovascular thrombectomy for patients wit
Introduction To end the COVID-19 pandemic, the WHO set a goal in 2021 to fully vaccinate 70% of the global population by mid-2022. We projected the COVID-19 vaccination trajectory in 52 African countries and compared the projected to the ‘actual’ or ‘observed’ coverage as of December 2022. We also estimated the required vaccination speed needed to have attained the WHO 70% coverage target by December 2022. Methods We obtained publicly available, country-reported daily COVID-19 vaccination data, covering the initial 9 months following the deployment of vaccines. We used a deterministi...
A combination of factors including migration, climate change and the encroachment of growing cities are associated with the extinction of species and a reduction in biodiversity. In Mexico maize landraces are an important source of germplasm that could be invaluable for future breeding programs in response a changing environment. Efforts to develop conservation strategies are hampered by the costs of housing and maintaining large germplasm collections. Effective criteria are therefore needed to identify rare genotypes that are in danger of being lost and to define minimal cost -effective core ...
The ongoing benefits of coronavirus disease 2019 (COVID-19) nonpharmaceutical interventions (NPIs) for respiratory infectious diseases in China are still unclear. We aimed to explore the changes in seven respiratory infectious diseases before, during, and after COVID-19 in China from 2010 to 2021. The monthly case numbers of seven respiratory infectious diseases were extracted to construct autoregressive integrated moving average (ARIMA) models. Eight indicators of NPIs were chosen from the COVID-19 Government Response Tracker system. The monthly case numbers of the respiratory diseases and th...
Australia commenced its COVID-19 vaccine program for children aged 12–15 years from July 2021 and for children aged 5–11 years from January 2022 with two primary doses of either Comirnaty (Pfizer–BioNTech BNT162b2, 10 μg for 5–11 years and 30 μg for 12–15 years) or Spikevax (Moderna mRNA-1273, 50 μg for 6–11 years and 100 μg for 12–15 years), 8 weeks apart. A booster dose is recommended for those aged 5–15 years with complex health conditions or severe immunocompromise.